In this video, Antonio Palumbo, MD, discusses results of the CASTOR trial, which studied daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Antonio Palumbo, MD
Advertisement
Articles by Antonio Palumbo, MD
Advertisement
Latest Updated Articles
New Standard of Care in Relapsed, Refractory Myeloma?Published: June 6th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
2
3 Things You Should Know About Single-Agent ADCs in TNBC Treatment
3
Response Rates Show Promise in Phase 1 Trial Involving ASCT in Metastatic PDAC
4
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
5
